Startup Funding Tracker
Home›People›Reid Huber
Reid Huber

Reid Huber

Director at Synnovation Therapeutics. Also a partner, third rock ventures and director at Terremoto and a director at Asher Biotherapeutics.

DirectorRoles at 3 startups
Reid Huber on LinkedIn
Updated Nov 10, 2026·Latest SEC filing Apr 22, 2026·Suggest an edit

About Reid Huber

Form D filings for Synnovation Therapeutics in 2023 list Reid Huber as director.

Form D filings also name Reid Huber as a partner, third rock ventures and director at Terremoto and a director at Asher Biotherapeutics.

Reid Huber first appears on SEC filings in 2021.

Experience

This experience comes from Reid Huber's profile and from SEC filings. For roles taken from filings, the years are when the filings name Reid Huber in the role, so the role may have started earlier or lasted longer.

Syremis Therapeutics Current
Director
2025 – Present
Synnovation Therapeutics, Inc. Current
Director
2023 – Present · Wilmington, DE
Rapport Therapeutics Current
Director
2022 – Present
Terremoto Biosciences, Inc. Current
Partner, Third Rock Ventures and director
2021 – Present · South San Francisco, CA
Develops targeted medicines for patients with cancer and genetic diseases.
Asher Biotherapeutics, Inc. Current
Director
2021 – Present · South San Francisco, CA
MOMA Therapeutics Current
Director
2020 – Present
Eastern New Enlgand Board of the American Cancer Society Current
Director
2020 – Present
insitro Current
Board Observer
2019 – Present
Partners HealthCare, Innovation Growth Board Current
Director
2019 – Present
Third Rock Ventures Current
Partner
2018 – Present
Merida Biosciences
Chairperson
2024 – 2026
Bellicum Pharmaceuticals, Inc.
Director
2014 – 2024
Tango Therapeutics
Director
2019 – 2023
The Andrew McDonough B+ Foundation
Director
2017 – 2019
Incyte
Executive Vice President, Chief Scientific Officer
2002 – 2018
Dupont Pharmaceuticals
Principal Research Scientist, Applied Biotechnology
1998 – 2002

Key Colleagues at Startups

The people Reid Huber works with at each company, as listed on that company's latest Form D.

Terremoto Biosciences, Inc. · Form D, Apr 22, 2026
MG
GL
Grace Lu
Executive officer
James Christensen
James Christensen
President and Chief Executive Officer, director
Peter Thompson
Peter Thompson
Co-founder and Director, Terremoto
DC
Charles Baum
Charles Baum
Executive Chairman
Asher Biotherapeutics, Inc. · Form D, Apr 16, 2024
CG
Craig Gibbs
Chief Executive Officer and director
ID
Ivana Djuretic
Executive officer and director
JT
Jeffrey Tong
Director
KE
Kyle Elrod
Executive officer
BD
ES
Elaine Sun
Director
AY
Andy Yeung
Executive officer
DS
Don O'Sullivan
Executive officer
IC
Ian Clark
Director
Synnovation Therapeutics, Inc. · Form D/A, Dec 21, 2023
LW
Liangxing Wu
Executive officer and director
WY
Wenqing Yao
CEO and director
TF
Ting Feng
Director

Sources

  1. SECTerremoto Biosciences, Inc. Form D, filed Apr 22, 2026
  2. SECAsher Biotherapeutics, Inc. Form D, filed Apr 16, 2024
  3. SECSynnovation Therapeutics, Inc. Form D/A, filed Dec 21, 2023